HBM BIOVENTURES CAYMAN LTD 13D/13G Filings for Ambrx Biopharma Inc. (AMAM)

HBM BIOVENTURES CAYMAN LTD 13D and 13G filings for Ambrx Biopharma Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		Transaction
Date		TypeCompany
Symbol		Filed By
Symbol		Shares Owned
% Owned		Shares Vs. Prev ReportView
2023-02-14
4:02 pm
Sale		2022-12-3113GAmbrx Biopharma Inc.
AMAM		HBM BIOVENTURES CAYMAN LTD8,400,000
3.100%		-8,456,567decrease
(-50.17%)		Filing
2022-02-11
4:03 pm
Sale		2021-12-3113GAmbrx Biopharma Inc.
AMAM		HBM BIOVENTURES CAYMAN LTD16,856,567
6.900%		-898,156decrease
(-5.06%)		Filing
2021-07-02
4:00 pm
Purchase		2021-06-2213GAmbrx Biopharma Inc.
AMAM		HBM BIOVENTURES CAYMAN LTD17,754,723
6.700%		17,754,723increase
(New Position)		Filing